The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Open accessAbstract
BACKGROUND: -altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: fusion-positive thyroid cancer, the percentage who had a response was 79% (95% CI, 54 to 94), and 1-year progression-free survival was 64% (95% CI, 37 to 82). The most common adverse events of grade 3 or higher were hypertension (in 21% of the patients), increased alanine aminotransferase level (in 11%), increased aspartate aminotransferase level (in 9%), hyponatremia (in 8%), and diarrhea (in 6%). Of all 531 patients treated, 12 (2%) discontinued selpercatinib owing to drug-related adverse events. CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cited by
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Leveraging large language models for decision support in personalized oncology
Benary, M., Wang, X. D., Schmidt, M., Soll, D., Hilfenhaus, G., Nassir, M., Sigler, C., Knödler, M., Keller, U., Beule, D., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.43689 · Cited by 306
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Self-citationCurrent Guidelines for Management of Medullary Thyroid Carcinoma
Kim, M., & Kim, B. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1082 · Cited by 101
Maniakas, A., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.020 · Cited by 80
Self-citation
Metadata
- Authors
- Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., Godbert, Y., Barlesi, F., Morris, J. C., Owonikoko, T. K., Tan, D. S. W., Gautschi, O., Weiss, J., de la Fouchardière, C., Burkard, M. E., Laskin, J., Taylor, M. H., Kroiss, M., Medioni, J., Goldman, J. W., Bauer, T. M., Levy, B., Zhu, V. W., Lakhani, N., Moreno, V., Ebata, K., Nguyen, M., Heirich, D., Zhu, E. Y., Huang, X., Yang, L., Kherani, J., Rothenberg, S. M., Drilon, A., Subbiah, V., Shah, M. H., & Cabanillas, M. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-08-27
- Volume
- 383
- Issue
- 9
- Pages
- 825-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3080978633
- Cited by
- 790
- References
- 1
- FWCI
- 73.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Selpercatinib in RET -Altered Thyroid Cancers. https://app.cochat.ai/papers/10.1056/nejmoa2005651
- The paper
- Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., Godbert, Y., Barlesi, F., Morris, J. C., Owonikoko, T. K., Tan, D. S. W., Gautschi, O., Weiss, J., de la Fouchardière, C., Burkard, M. E., . . . Cabanillas, M. E. (2020). Efficacy of Selpercatinib in RET -Altered Thyroid Cancers. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2005651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
